Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ono Pharmaceutical And Astellas Launch Osteoporosis Drug

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Ono Pharmaceutical and Tokyo-based Astellas April 7 launched osteoporosis drug RECALBON/Boneteo (minodronic acid) in Japan. Jointly developed by the two, the treatment obtained Japanese approval Jan. 21. The side effects include stomach and abdominal discomfort, abdominal pain, reduced blood calcium and gastritis. Severe side effects include duodenal and gastric ulcers. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071556

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel